| Literature DB >> 20150965 |
Salvatore Cappadona1, Paolo Nanni, Marco Benevento, Fredrik Levander, Piera Versura, Aldo Roda, Sergio Cerutti, Linda Pattini.
Abstract
Label-free LC-MS analysis allows determining the differential expression level of proteins in multiple samples, without the use of stable isotopes. This technique is based on the direct comparison of multiple runs, obtained by continuous detection in MS mode. Only differentially expressed peptides are selected for further fragmentation, thus avoiding the bias toward abundant peptides typical of data-dependent tandem MS. The computational framework includes detection, alignment, normalization and matching of peaks across multiple sets, and several software packages are available to address these processing steps. Yet, more care should be taken to improve the quality of the LC-MS maps entering the pipeline, as this parameter severely affects the results of all downstream analyses. In this paper we show how the inclusion of a preprocessing step of background subtraction in a common laboratory pipeline can lead to an enhanced inclusion list of peptides selected for fragmentation and consequently to better protein identification.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20150965 PMCID: PMC2817556 DOI: 10.1155/2010/131505
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Figure 1Typical pipeline for comparative LC-MS analysis. (a) The preprocessing step of noise rejection is shown as optional to the common workflow. (b) Details of the bioinformatic steps: in black the standard workflow, in red the alternative workflow subsequent to noise rejection, and in green the comparison of the results obtained by the two approaches.
Alignment of technical replicates. Mass Window = 0.2 Th, Scan Window = 250 scans, Min Charge = 2+.
| Total | Only I | Only II | Only III | I-II | I-III | II-III | I-II-III | ||
|---|---|---|---|---|---|---|---|---|---|
| H1 I-II-III | 4167 | 767 | 568 | 564 | 315 | 288 | 208 | 1457 | |
| 5736 | 1061 | 915 | 1018 | 379 | 361 | 338 | 1664 | ||
|
% | |||||||||
| H2 I-II-III | 4476 | 890 | 933 | 625 | 208 | 420 | 347 | 1053 | |
| 5783 | 1178 | 1307 | 925 | 228 | 519 | 472 | 1154 | ||
|
% | |||||||||
| HDE1 I-II-III | 4456 | 861 | 889 | 607 | 314 | 475 | 245 | 1065 | |
| 6324 | 1301 | 1386 | 1051 | 384 | 650 | 347 | 1205 | ||
|
% | |||||||||
| HDE2 I-II-III | 3921 | 842 | 543 | 563 | 345 | 253 | 288 | 1087 | |
| 5087 | 1068 | 754 | 962 | 356 | 299 | 394 | 1254 | ||
|
% | |||||||||
Figure 2Results of the alignment of the original and the filtered files of all 12 LC-MS run. Common: features found in both maps; processed: features found only after noise rejection; unprocessed: features found only in the original maps.
Figure 3KL ratio of corresponding peptides after the alignment of the processed and the unprocessed maps of HDE2III. Most of the peptides have KLClean < KLOriginal.
Figure 4Details of unprocessed and processed LC-MS maps. Despite its high intensity, the highlighted doubly charged peptide QLCSFEIYEVPWEDR (m/z 986.04) was not assigned a charge in the original map, because some of its isotopes were altered by the chemical noise.
(a) Over-expressed proteins in hyperevaporative dry eye patients
| Name | Entry name | m/z | Charge | Sequence | Score | |
|---|---|---|---|---|---|---|
| Unprocessed | Processed | |||||
| Hemoglobin subunit bete | HBB_HUMAN | 590.89 | 2 | GVANALAHKYH | 16 | 18 |
| 862.91 | 3 | GTFATLSELHCDKLHVDPENFR | 40 | 59 | ||
| 637.89 | 2 | LLVVYPWTQR | 31 | 30 | ||
| 737.508 | 3 | TLSELHCDKLHVDPENFR | 51 | — | ||
| 725.44 | 2 | VVAGVANALAHKYH | 33 | 27 | ||
| 835.59 | 2 | VLGAFSDGLAHLDNLK | — | 74 | ||
| 1030.15 | 2 | FFESFGDLSTPDAVMGNPK | — | 17 | ||
| 888.95 | 2 | LLGNVLVCVLAHHFGK | — | 49 | ||
| 899.64 | 2 | KVLGAFSDGLAHLDNLK | — | 53 | ||
| 575.39 | 2 | VVAGVANALAHK | — | 28 | ||
| 524.805 | 2 | VVYPWTQR | — | 14 | ||
| 810.203 | 3 | FATLSELHCDKLHVDPENFR | — | 15 | ||
| 626.39 | 2 | AGVANALAHKYH | — | 17 | ||
| 786.03 | 2 | LGAFSDGLAHLDNLK | — | 22 | ||
| ALBU_HUMAN | 756.49 | 2 | VPQVSTPTLVEVSR | 47 | — | |
| 613.88 | 2 | FKDLGEENFK | 5 | 17 | ||
| 717.46 | 2 | KECCEKPLLEK | 51 | 23 | ||
| 820.49 | 2 | KVPQVSTPTLVEVSR | — | 85 | ||
| 722.35 | 2 | YICENQDSISSK | — | 30 | ||
| 871.95 | 2 | HPYFYAPELLFFAK | — | 35 | ||
| 926.8 | 3 | LVRPEVDVMCTAFHDNEETFLKK | — | 29 | ||
| Hemoglobin subunit alpha | HBA_HUMAN | 523.96 | 3 | FPHFDLSHGSAQVK | — | 2 |
| 663.37 | 2 | HFDLSHGSAQVK | — | 30 | ||
| 942.98 | 3 | DALTNAVAHVDDMPNALSALSDLHAHK | — | 46 | ||
| 785.92 | 4 | KVADALTNAVAHVDDMPNALSALSDLHAHK | — | 6 | ||
| — | ||||||
| — | ||||||
(b) Under-expressed proteins in hyperevaporative dry eye patients
| Name | Entry name | m/z | Charge | Sequence | Score | |
|---|---|---|---|---|---|---|
| Unprocessed | Processed | |||||
| LCN1_HUMAN | 669.86 | 2 | TDEPGKYTADGGK | 34 | 48 | |
| 722.94 | 2 | YCEGELHGKPVR | 16 | — | ||
| 707.44 | 3 | DHYIFYCEGELHGKPVR | 97 | 36 | ||
| 643.64 | 4 | SHVKDHYIFYCEGELHGKPVR | 30 | 15 | ||
| 874.54 | 2 | NNLEALEDFEKAAGAR | 67 | 84 | ||
| 934.6 | 2 | YIFYCEGELHGKPVR | 14 | — | ||
| 496.84 | 2 | GELHGKPVR | — | 10 | ||
| 561.36 | 2 | EGELHGKPVR | — | 20 | ||
| 593.88 | 2 | AVLEKTDEPGK | — | 28 | ||
| 641.38 | 2 | CEGELHGKPVR | — | 2 | ||
| 796.48 | 2 | FYCEGELHGKPVR | — | 36 | ||
| 885.5 | 2 | SDEEIQDVSGTWYLK | — | 56 | ||
| 1171.21 | 2 | HHLLASDEEIQDVSGTWYLK | — | 102 | ||
| 857.88 | 3 | SHVKDHYIFYCEGELHGKPVR | — | 47 | ||
| Polymeric immunoglobulin receptor | PIGR_HUMAN | 703.95 | 2 | VLDSGFREIENK | 38 | 44 |
| 876.04 | 2 | TVTINCPFKTENAQK | 11 | — | ||
| 854.01 | 2 | QSSGENCDVVVNTLGK | 78 | 47 | ||
| 573.35 | 2 | QGARGGCITLI | — | 3 | ||
| 775.97 | 2 | TINCPFKTENAQK | — | 6 | ||
| TRFL_HUMAN | 694.94 | 2 | GPQYVAGITNLKK | 16 | — | |
| 624.37 | 2 | WCAVGEQELR | 15 | — | ||
| 790.48 | 2 | NLLFNDNTECLAR | 37 | — | ||
| 874.03 | 2 | RSVQWCAVSQPEATK | 74 | — | ||
| 630.91 | 2 | GPQYVAGITNLK | — | 21 | ||
| 702.89 | 2 | QWCAVSQPEATK | — | 9 | ||
| 706.93 | 2 | PIQCIQAIAENR | — | 62 | ||
| 841.97 | 2 | CSTSPLLEACEFLR | — | 70 | ||
| 886.06 | 2 | RDSPIQCIQAIAENR | — | 6 | ||
| 953.55 | 3 | SQQSSDPDPNCVDRPVEGYLAVAVVR | — | 30 | ||
| 982.55 | 2 | SASCVPGADKGQFPNLCR | — | 56 | ||
| ALBU_HUMAN | 1020.23 | 2 | VFDEFKPLVEEPQNLIK | 38 | — | |
| 773.99 | 2 | LKECCEKPLLEK | 35 | — | ||
| Ig kappa chain C region | IGKC_HUMAN | 714.45 | 3 | HKVYACEVTHQGLSSPVTK | — | 79 |
| 1071.18 | 2 | HKVYACEVTHQGLSSPVTK | — | 34 | ||
| — | ||||||
| — | ||||||
| Proline-rich protein 4 | PROL4_HUMAN | 815.2 | 2 | DRPARHPQEQPLW | 43 | 15 |
| 801.48 | 2 | FPSVSLQEASSFFR | — | 84 | ||
| 537.66 | 3 | PSVSLQEASSFFRR | — | 13 | ||
| 598.38 | 2 | HPPPPPFQNQQRPPR | — | 15 | ||
| 552.68 | 3 | PPPPPFQNQQRPPR | — | 27 | ||
| SG1D1_HUMAN | 869.57 | 1 | APLEAVAAK | — | 24 | |
| 572.9 | 2 | FKAPLEAVAAK | — | 39 | ||
| 988.67 | 2 | QALGSEITGFLLAGKPVFK | — | 96 | ||
| 712.8 | 3 | CQALGSEITGFLLAGKPVFK | — | 71 | ||
| 622.86 | 2 | KCVDTMAYEK | — | 10 | ||
| — | ||||||
| — | ||||||
| SG2A1_HUMAN | 732.95 | 2 | FKQCFLNQSHR | — | 45 | |
| 969 | 2 | ELLQEFIDSDAAAEAMGK | — | 81 | ||
| 977.54 | 2 | ELLQEFIDSDAAAEA | — | 7 | ||
| — | ||||||
| — | ||||||
| Cystatin-S | CYTS_HUMAN | 964.05 | 2 | PNLDTCAFHEQPELQK | — | 21 |
| 685.74 | 3 | PNLDTCAFHEQPELQKK | — | 29 | ||
| 1135.65 | 2 | SQPNLDTCAFHEQPELQKK | — | 6 | ||
| 986.04 | 2 | QLCSFEIYEVPWEDR | — | 67 | ||
| — | ||||||
| — | ||||||